IMNM — Immunome Inc · catalysts, narrative & risks

Overview

Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company developing antibody-drug conjugates (ADCs), radioligand therapies, and the small-molecule gamma secretase inhibitor varegacestat (formerly AL102) for desmoid tumors [3], [13], [16]. The stock closed around $17.40–$17.58 in mid-October 2026, with a market cap of ~$2.12B as of 2026-10-25 [background], [8], [9]. Below are the recent catalysts, bull/bear narratives, risks, and scheduled events, drawn from primary and secondary sources.

Recent Catalysts (July–October 2026)